Genmab A/S (NASDAQ:GMAB) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research note released on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $41.50 target price on the stock.

Several other research firms have also recently weighed in on GMAB. Morgan Stanley assumed coverage on Genmab A/S in a research report on Monday. They set an “equal weight” rating and a $34.00 price objective on the stock. Truist Financial restated a “buy” rating and issued a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price target on shares of Genmab A/S in a research report on Wednesday, January 28th. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Finally, Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.10.

Genmab A/S Trading Down 0.1%

Genmab A/S stock opened at $30.00 on Tuesday. The company has a market capitalization of $19.27 billion, a price-to-earnings ratio of 12.77, a PEG ratio of 17.63 and a beta of 0.90. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $35.43. The stock’s 50 day moving average is $32.30 and its 200-day moving average is $29.88.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently made changes to their positions in GMAB. CIBC Private Wealth Group LLC increased its stake in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 616 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. CWM LLC raised its holdings in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after buying an additional 603 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after buying an additional 1,143 shares during the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in shares of Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after buying an additional 780 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S News Summary

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Company initiated a targeted share buy‑back to satisfy Restricted Stock Unit obligations (repurchase of up to 342,130 shares, max ~725 million DKK), which reduces float and signals capital allocation support for the stock. Genmab Announces Initiation of Share Buy-Back Program
• Positive Sentiment: Q4 results modestly beat EPS expectations: reported $0.47 EPS vs. $0.46 consensus, with revenue roughly in line at ~$1.06B and strong margins — a near-term fundamental positive. Q4 Slide Deck
• Positive Sentiment: Jefferies initiated coverage with a Buy and $41.50 target, representing meaningful upside vs. the current level — this can attract buyers and support sentiment. Benzinga
• Neutral Sentiment: Genmab published its 2025 Annual Report and filed Form 20‑F with the SEC — increases disclosure and transparency but is unlikely to move the stock materially on its own. Genmab Publishes 2025 Annual Report Genmab Files Annual Report (20-F)
• Neutral Sentiment: Morgan Stanley initiated coverage with an Equal Weight and $34 target — a mixed signal (coverage brings attention; Equal Weight is not a buy). Benzinga
• Neutral Sentiment: Investor materials and earnings‑call presentation posted (Seeking Alpha / slide deck) for deeper review of 2025 results and 2026 outlook. Useful for due diligence but not a headline mover. Earnings Presentation
• Neutral Sentiment: Short‑interest data reported appears anomalous (shows zero shares), so it offers no actionable signal to traders today.
• Negative Sentiment: Genmab updated FY‑2026 guidance but the published figures appear garbled/ inconsistent (revenue cited as “4.1–4.4 billionillion” vs. a cited consensus of “18.2 billionillion”). The unclear/likely erroneous guidance disclosure has likely increased investor uncertainty and could pressure the stock until clarified.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.